Number of pages: 100 | Report Format: PDF | Published date: May 01, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
CAGR |
4.2% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Type, Treatment Type, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Ehlers-Danlos syndrome market is expected to grow at a revenue CAGR of 4.2% from 2023 to 2031.
Ehlers-Danlos Syndrome Market Fundamentals
Ehlers-Danlos syndrome (EDS) is a group of rare genetic disorders that affect connective tissues in the body. Connective tissues provide strength and elasticity to various body parts, including skin, tendons, ligaments, blood vessels, and organs. Ehlers-Danlos syndrome can affect any part of the body, but the most common areas affected are the joints and skin. There are several types of Ehlers-Danlos syndrome, each with unique features, but all involve abnormal collagen synthesis, a key component of connective tissues. The severity of Ehlers-Danlos syndrome can vary widely, and some types are associated with life-threatening complications. Common Ehlers-Danlos syndrome symptoms include joint hypermobility, easily bruised, stretched, or scarred skin, and chronic pain. Individuals with Ehlers-Danlos syndrome may also experience joint dislocations, gastrointestinal problems, and cardiovascular issues. Ehlers-Danlos syndrome is a genetic condition, and most types are inherited in an autosomal dominant pattern. A person only needs to inherit one copy of the mutated gene from one parent to develop the condition. However, some types of Ehlers-Danlos syndrome can be inherited in an autosomal recessive pattern, which means that a person needs to inherit two copies of the mutated gene (one from each parent) to develop the condition.
Ehlers-Danlos Syndrome Market Dynamics
The rising prevalence of Ehlers-Danlos syndrome globally is increasing the demand for early diagnosis and treatment of Ehlers-Danlos syndrome. Currently, there are no approved treatments for Ehlers-Danlos syndrome, and existing treatments focus on managing symptoms rather than targeting the underlying cause of the disease. This creates a significant unmet medical need and drives the demand for new and effective treatments. Identifying genetic mutations that cause Ehlers-Danlos syndrome has opened up new opportunities for developing targeted therapies and gene-based treatments. This has led to a growing interest in gene therapy and other gene-editing technologies, which could cure Ehlers-Danlos syndrome by repairing or replacing the faulty genes responsible for the disease.
Moreover, the identification of genetic mutations that cause Ehlers-Danlos syndrome has opened up new opportunities for developing targeted therapies and gene-based treatments. This has led to a growing interest in gene therapy and other gene-editing technologies, which could cure Ehlers-Danlos syndrome by repairing or replacing the faulty genes responsible for the disease. Advancements in medical technology, such as regenerative medicine, personalized medicine, and drug delivery systems, have created new opportunities for treating Ehlers-Danlos syndrome. Regenerative medicine, in particular, can potentially restore the strength and elasticity of connective tissues affected by Ehlers-Danlos syndrome. The growing advocacy and awareness efforts of patients, families, and support groups have led to increased funding for research and development in the Ehlers-Danlos syndrome market. This has also helped raise public awareness of the condition, leading to increased diagnosis rates and treatment demand.
However, the high cost of developing new treatments for Ehlers-Danlos syndrome is a significant restraint on the market. Due to the small patient population, the cost of clinical trials is high, and there is no guarantee of success. This can deter companies from investing in the development of new therapies. There is limited or no reimbursement for many treatments used to manage Ehlers-Danlos syndrome symptoms. This can be a significant barrier to patients seeking treatment, hampering the Ehlers-Danlos syndrome market growth.
Ehlers-Danlos Syndrome Market Ecosystem
The global Ehlers-Danlos syndrome market is analyzed from three perspectives: type, treatment type, and region.
Ehlers-Danlos Syndrome Market by Type
[7412]
Based on the types, the global Ehlers-Danlos syndrome market is segmented into classical EDS, hypermobile EDS, cardiovascular EDS, kyphoscoliotic EDS, and others.
The hypermobile EDS segment dominated the Ehlers-Danlos syndrome market with the largest revenue share. Hypermobile EDS is the most common subtype of Ehlers-Danlos syndrome, accounting for approximately 90% of all cases. This higher prevalence translates into a larger patient population, which can make it more attractive for pharmaceutical companies to develop treatments specifically for this subtype. Patients with hypermobile EDS often experience more severe symptoms than other subtypes, including chronic pain and joint instability. This can lead to a higher demand for treatment and therapies to manage these symptoms. Diagnosing hypermobile EDS can be challenging, as no specific genetic test exists for this subtype. Instead, diagnosis is based on clinical examination and the presence of specific symptoms. This can lead to misdiagnosis and treatment delays, making it more challenging for patients with hypermobile EDS to manage their symptoms. This creates a greater need for effective treatments and therapies.
The classical EDS segment also accounted for a considerable revenue share of the Ehlers-Danlos syndrome market in 2022. The classical EDS subtype represents a sizable proportion of the Ehlers-Danlos syndrome market. It is the second most common type of Ehlers-Danlos syndrome. Classical EDS has unique clinical features, including hypermobility, skin hyperextensibility, and scarring. This makes it distinguishable from other subtypes of EDS and creates a need for targeted treatments and therapies. Classical EDS can be associated with significant morbidity, including joint and skin problems, gastrointestinal issues, and cardiovascular complications. This creates a demand for effective treatments and therapies to manage these symptoms. Classical EDS is caused by mutations in the COL5A1 and COL5A2 genes, which can be identified through genetic testing. This can lead to earlier diagnosis and treatment, attracting patients and healthcare providers.
Ehlers-Danlos Syndrome Market by Treatment Type
Based on the treatment types, the global Ehlers-Danlos syndrome market is segmented into pain management drugs, bone density management drugs, gastrointestinal drugs, cardiovascular disease drugs, psychiatric drugs, and others.
The pain management drugs segment accounted for a significant revenue share of the Ehlers-Danlos syndrome market. Pain is one of the most common and debilitating symptoms of Ehlers-Danlos syndrome, particularly in the hypermobile and classical subtypes. Patients with Ehlers-Danlos syndrome may experience chronic pain, joint pain, and muscle pain, which can significantly impact their quality of life. As a result, there is a high demand for effective pain management treatments. Currently, there are no approved treatments for any subtype of Ehlers-Danlos syndrome. This creates a significant unmet need in the market for effective pain management therapies, which has led to the development of a wide range of pain management drugs and treatments. Due to the complexity of Ehlers-Danlos syndrome and the range of symptoms that patients experience, pain management often requires a multimodal approach that combines multiple drugs and therapies. This can include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and corticosteroids. This creates a diverse market for pain management drugs and therapies. Ehlers-Danlos syndrome is a chronic condition that requires long-term management of symptoms. This creates a sustained demand for pain management drugs and therapies over an extended period, boosting segmental growth.
The bone density management drugs segment accounted for a considerable Ehlers-Danlos syndrome market's revenue share. Patients with Ehlers-Danlos syndrome, particularly those with the classical subtype, are at a higher risk of skeletal abnormalities such as osteoporosis, osteopenia, and scoliosis. This creates a need for effective bone density management drugs and treatments. Bone-related complications in Ehlers-Danlos syndrome can result in significant morbidity, including fractures, chronic pain, and decreased mobility. As a result, patients with Ehlers-Danlos syndrome are more likely to seek out and demand effective treatments for their bone-related complications. Ehlers-Danlos syndrome is a complex condition that often requires a disease management approach that addresses multiple symptoms and complications. As a result, there is a need for bone density management drugs that can be used in combination with other treatments to manage the disease as a whole.
Ehlers-Danlos Syndrome Market by Region
The global Ehlers-Danlos syndrome market has been segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest Ehlers-Danlos syndrome market size in terms of revenue generation. The prevalence of Ehlers-Danlos syndrome is increasing in North America. This growing patient population is a significant market driver, creating a demand for effective treatments and therapies. According to the National Organization for Rare Disorders, the incidence of all Ehlers-Danlos syndrome types range from 1/ 2,500 to 1/5,000 births. There is a high awareness and understanding of Ehlers-Danlos syndrome among healthcare providers and the general public in North America. This has led to an increased demand for treatments and research into the underlying causes of the disease. Besides, North America has a well-developed healthcare infrastructure with advanced medical facilities, access to specialized healthcare providers, and many clinical trials. This makes it an attractive market for companies developing treatments and therapies for Ehlers-Danlos syndrome. The regulatory environment in North America is favorable for developing and approving new treatments and therapies for rare diseases like Ehlers-Danlos syndrome. This creates opportunities for companies to bring innovative treatments to market. Strong patient advocacy groups in North America are dedicated to raising awareness of Ehlers-Danlos syndrome, providing support and resources for patients, and advocating for research and development of new treatments.
Ehlers-Danlos Syndrome Competitive Landscape
The prominent players operating in the global Ehlers-Danlos syndrome market are:
Ehlers-Danlos Syndrome Strategic Developments
Ehlers-Danlos syndrome (EDS) is a group of rare genetic disorders that affect connective tissues in the body. Connective tissues provide strength and elasticity to various body parts, including skin, tendons, ligaments, blood vessels, and organs. Ehlers-Danlos syndrome can affect any part of the body, but the most common areas affected are the joints and skin.
The global Ehlers-Danlos syndrome market growth is estimated at a revenue CAGR of 4.2%.
The prominent players operating in the global Ehlers-Danlos syndrome market are Aytu BioPharma, Acer Therapeutics, Hisamitsu Pharmaceuticals Co., Inc., AstraZeneca Plc, and Genentech, Inc.
North America has the largest market share in terms of revenue. Asia Pacific has the fastest growth rate, the key growth region due to the surge in Ehlers-Danlos syndrome industry trends.
The growing prevalence of Ehlers-Danlos syndrome and the rise in the R&D related to Ehlers-Danlos syndrome are some of the driving factors of the market.
*Insights on financial performance are subject to the availability of information in the public domain